Three states and a handful of cities and counties have objected to a plan that would estimate the total value of legal claims against bankrupt opioid manufacturer Insys Therapeutics Inc.

Insys, which filed for Chapter 11 bankruptcy protection June 10, filed a motion to estimate the costs of about 1,000 lawsuits brought against the Phoenix-based company over the opioid crisis. The procedure would preserve funds and “fix aggregate amounts of particular categories of claims on an expedited basis,” according to the motion.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]